Prime Editing and CRISPR Market by Service (Cell Line Engineering, Genome Regulation, Gene Editing, and Gene-Modified Cell Therapy), Application (Biomedical Research & Therapy, Agricultural Research, and Others), and End User (Academic Institutes, Biotechnology & Pharma Companies, and Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2021––2030
The global prime editing and CRISPR market was valued at $2,694.2 million in 2020, and is estimated to reach $23,493.0 million by 2030, growing at a CAGR of 24.3% from 2021 to 2030.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a genetic tool used for editing of genome. Prime editing is considered as the developed version of CRISPR/Cas9 genome editing technology. It is a genome editing technology, which uses fusion protein of Cas9-nickase and reverse transcriptase for treatment of genetic defects. It is a new molecular gadget capable of removing and cutting any base pair and adding long segments of DNA without breaking both strands of the helix. Prime editing and CRISPR are used as molecular scissors to develop new therapies for treatment of chronic and genetic diseases. This technology helps in the treatment of rare genetic disease such as sickle cell anemia, cystic fibrosis, correction in point mutation and chronic disease such as lung cancer.
The global prime editing and CRISPR market is majorly driven by an alarming increase in prevalence of genomic and chronic diseases such as sickle cell anemia, cystic fibrosis and lung cancer; rise in government funds for genomic projects; surge in demand for genetically mutated crops; advancements in R&D of genes; and rise in awareness regarding genetic engineering. For instance, according to the World Health Organizations (WHO), in 2020, approximately, 10 million people dieddue to various types of cancer. As per data published by a Cystic fibrosis foundation (Cff), in 2019, a total of 70,000 population in the world was diagnosed with cystic fibrosis and more than 1000 new cases of cystic fibrosis were reported each year. Moreover, surge in demand for genetic engineering in biomedical research and rise in need for gene editing drive growth of the market. Thus, increase in prevalence of genetic-based disease and surge in demand for gene manipulation are the factors expected to propel growth of the market.
Rise in funding from private & government organizations to genomic project and increase in application in genetically mutated crops are the major factors that drive the growth of the global prime editing and CRISPR market. Moreover, surge in incidences of diseases such as cancer significantly contributes toward the market growth, owing to the fact that gene insertion and deletion technique is used in treatment of several chronic diseases. Rise in genomic research activities acts as a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support regenerative medical research, which is expected to boost the market growth. Moreover, in 2021, SingHealth Duke-NUS Academic Medical Centre launched advanced regenerative medicine and introduced cellular therapy to enhance patient care. The project aims to explore regenerative cell therapy for treatment of blood cancers, heart failure, and eye degeneration. On the contrary, advancements in R&D for genetic engineering technology in emerging nations are anticipated to provide lucrative opportunities for the market expansion. For instance, in 2021, Scientist at US San Francisco, UC Berkeley launched first clinical trial of CRISPR gene correction therapy in patients suffering from sickle cell disease.
On the contrary, lack of safety concerns and ethical issues regarding gene editing in human germline are the factors anticipated to hinder the market growth during the forecast period. Decrease in cost of DNA is sequenced, which leads to enhancement of genomic research project and increase in research expenditure. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity for the prime editing and CRISPR market.
The global prime editing and CRISPR market is segmented into service, application, end user, and region. By service, the market is categorized into cell line engineering, genome regulation, gene editing and gene-modified cell therapy. By application, it is divided into biomedical research & therapy, agricultural research, and others. By end user, the market is bifurcated into academic institutions, biotechnology & pharma companies, and contract research organizations. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global prime editing and CRISPR market are Beam Therapeutics, CRISPR Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies (IDT), Intellia Therapeutics Inc., Inscripta, Precision Bioscience, Sangoma Therapeutics, and Synthego Corporation.
KEY BENEFITS FOR STAKEHOLDERS
By Service
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a genetic tool used for editing of genome. Prime editing is considered as the developed version of CRISPR/Cas9 genome editing technology. It is a genome editing technology, which uses fusion protein of Cas9-nickase and reverse transcriptase for treatment of genetic defects. It is a new molecular gadget capable of removing and cutting any base pair and adding long segments of DNA without breaking both strands of the helix. Prime editing and CRISPR are used as molecular scissors to develop new therapies for treatment of chronic and genetic diseases. This technology helps in the treatment of rare genetic disease such as sickle cell anemia, cystic fibrosis, correction in point mutation and chronic disease such as lung cancer.
The global prime editing and CRISPR market is majorly driven by an alarming increase in prevalence of genomic and chronic diseases such as sickle cell anemia, cystic fibrosis and lung cancer; rise in government funds for genomic projects; surge in demand for genetically mutated crops; advancements in R&D of genes; and rise in awareness regarding genetic engineering. For instance, according to the World Health Organizations (WHO), in 2020, approximately, 10 million people dieddue to various types of cancer. As per data published by a Cystic fibrosis foundation (Cff), in 2019, a total of 70,000 population in the world was diagnosed with cystic fibrosis and more than 1000 new cases of cystic fibrosis were reported each year. Moreover, surge in demand for genetic engineering in biomedical research and rise in need for gene editing drive growth of the market. Thus, increase in prevalence of genetic-based disease and surge in demand for gene manipulation are the factors expected to propel growth of the market.
Rise in funding from private & government organizations to genomic project and increase in application in genetically mutated crops are the major factors that drive the growth of the global prime editing and CRISPR market. Moreover, surge in incidences of diseases such as cancer significantly contributes toward the market growth, owing to the fact that gene insertion and deletion technique is used in treatment of several chronic diseases. Rise in genomic research activities acts as a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support regenerative medical research, which is expected to boost the market growth. Moreover, in 2021, SingHealth Duke-NUS Academic Medical Centre launched advanced regenerative medicine and introduced cellular therapy to enhance patient care. The project aims to explore regenerative cell therapy for treatment of blood cancers, heart failure, and eye degeneration. On the contrary, advancements in R&D for genetic engineering technology in emerging nations are anticipated to provide lucrative opportunities for the market expansion. For instance, in 2021, Scientist at US San Francisco, UC Berkeley launched first clinical trial of CRISPR gene correction therapy in patients suffering from sickle cell disease.
On the contrary, lack of safety concerns and ethical issues regarding gene editing in human germline are the factors anticipated to hinder the market growth during the forecast period. Decrease in cost of DNA is sequenced, which leads to enhancement of genomic research project and increase in research expenditure. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity for the prime editing and CRISPR market.
The global prime editing and CRISPR market is segmented into service, application, end user, and region. By service, the market is categorized into cell line engineering, genome regulation, gene editing and gene-modified cell therapy. By application, it is divided into biomedical research & therapy, agricultural research, and others. By end user, the market is bifurcated into academic institutions, biotechnology & pharma companies, and contract research organizations. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global prime editing and CRISPR market are Beam Therapeutics, CRISPR Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies (IDT), Intellia Therapeutics Inc., Inscripta, Precision Bioscience, Sangoma Therapeutics, and Synthego Corporation.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the global prime editing and CRISPR market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global prime editing and CRISPR market.
By Service
- Cell Line Engineering
- Genome Regulation
- Gene Editing
- Gene-Modified Cell Therapy
- Biomedical Research & Therapy
- Agricultural Research
- Others
- Academic Institutes
- Biomedical Research & Therapy
- Agricultural Research
- Others
- Biotechnology & Pharma Companies
- Biomedical Research & Therapy
- Agricultural Research
- Others
- Contract Research Organizations
- Biomedical Research & Therapy
- Agricultural Research
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Beam Therapeutics
- CRISPR Therapeutics
- GenScript Biotech
- Horizon Discovery
- Integrated DNA Technologies (IDT
- Intellia Therapeutics Inc.,
- Inscripta
- Precision Bioscience
- Sangoma Therapeutics
- Synthego Corporation
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Advancements in R&D in genetic engineering
3.5.1.2.Increase in demand for genetically modified crops
3.5.1.3.Surge in prevalence of chronic and genetic diseases
3.5.2.Restraints
3.5.2.1.Legal and ethical issues
3.5.2.2.Lack of safety toward gene editing
3.5.3.Opportunity
3.5.3.1.Increase in R&D by major key players and decrease in cost of genomic sequencing
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the prime editing and CRISPR market
CHAPTER 4:PRIME EDITING AND CRISPR MARKET, BY SERVICE
4.1.Overview
4.1.1.Market size and forecast
4.2.Cell line engineering
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Genome Regulation
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Gene editing
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Gene-modified cell therapy
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:PRIME EDITING AND CRISPR MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Biomedical research and therapy
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Agricultural Research
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Others
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
CHAPTER 6:PRIME EDITING AND CRISPR MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Academic institutions
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.2.4.Academic institutions, by application
6.3.Biotechnology & pharma companies
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.3.4.Biotechnology & pharma companies, by application
6.4.Contract Research Organizations
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
6.4.4.Contract research organizations, by application
CHAPTER 7:PRIME EDITING AND CRISPR MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America prime editing and CRISPR market, by service
7.2.3.North America prime editing and CRISPR market, by application
7.2.4.North America prime editing and CRISPR market, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. prime editing and CRISPR market, by service
7.2.5.1.2.U.S. prime editing and CRISPR market, by application
7.2.5.1.3.U.S. prime editing and CRISPR market, by end user
7.2.5.2.Canada
7.2.5.2.1.Canada prime editing and CRISPR market, by service
7.2.5.2.2.Canada prime editing and CRISPR market, by application
7.2.5.2.3.Canada prime editing and CRISPR market, by end user
7.2.5.3.Mexico
7.2.5.3.1.Mexico prime editing and CRISPR market, by service
7.2.5.3.2.Mexico prime editing and CRISPR market, by application
7.2.5.3.3.Mexico prime editing and CRISPR market, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe prime editing and CRISPR market, by service
7.3.3.Europe prime editing and CRISPR market, by application
7.3.4.Europe prime editing and CRISPR market, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany prime editing and CRISPR market, by service
7.3.5.1.2.Germany prime editing and CRISPR market, by application
7.3.5.1.3.Germany prime editing and CRISPR market, by end user
7.3.5.2.France
7.3.5.2.1.France prime editing and CRISPR market, by service
7.3.5.2.2.France prime editing and CRISPR market, by application
7.3.5.2.3.France prime editing and CRISPR market, by end user
7.3.5.3.UK
7.3.5.3.1.UK prime editing and CRISPR market, by service
7.3.5.3.2.UK prime editing and CRISPR market, by application
7.3.5.3.3.UK prime editing and CRISPR market, by end user
7.3.5.4.Italy
7.3.5.4.1.Italy prime editing and CRISPR market, by service
7.3.5.4.2.Italy prime editing and CRISPR market, by application
7.3.5.4.3.Italy prime editing and CRISPR market, by end user
7.3.5.5.Spain
7.3.5.5.1.Spain prime editing and CRISPR market, by service
7.3.5.5.2.Spain prime editing and CRISPR market, by application
7.3.5.5.3.Spain prime editing and CRISPR market, by end user
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe prime editing and CRISPR market, by service
7.3.5.6.2.Rest of Europe prime editing and CRISPR market, by application
7.3.5.6.3.Rest of Europe prime editing and CRISPR market, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific prime editing and CRISPR market, by service
7.4.3.Asia-Pacific prime editing and CRISPR market, by application
7.4.4.Asia-Pacific prime editing and CRISPR market, by end user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan prime editing and CRISPR market, by service
7.4.5.1.2.Japan prime editing and CRISPR market, by application
7.4.5.1.3.Japan prime editing and CRISPR market, by end user
7.4.5.2.China
7.4.5.2.1.China prime editing and CRISPR market, by service
7.4.5.2.2.China prime editing and CRISPR market, by application
7.4.5.2.3.China prime editing and CRISPR market, by end user
7.4.5.3.Australia
7.4.5.3.1.Australia prime editing and CRISPR market, by service
7.4.5.3.2.Australia prime editing and CRISPR market, by application
7.4.5.3.3.Australia prime editing and CRISPR market, by end user
7.4.5.4.India
7.4.5.4.1.India prime editing and CRISPR market, by service
7.4.5.4.2.India prime editing and CRISPR market, by application
7.4.5.4.3.India prime editing and CRISPR market, by end user
7.4.5.5.South Korea
7.4.5.5.1.South Korea prime editing and CRISPR market, by service
7.4.5.5.2.South Korea prime editing and CRISPR market, by application
7.4.5.5.3.South Korea prime editing and CRISPR market, by end user
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific prime editing and CRISPR market, by service
7.4.5.6.2.Rest of Asia-Pacific prime editing and CRISPR market, by application
7.4.5.6.3.Rest of Asia-Pacific prime editing and CRISPR market, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA prime editing and CRISPR market, by service
7.5.3.LAMEA prime editing and CRISPR market, by application
7.5.4.LAMEA prime editing and CRISPR market, by end user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil prime editing and CRISPR market, by service
7.5.5.1.2.Brazil prime editing and CRISPR market, by application
7.5.5.1.3.Brazil prime editing and CRISPR market, by end user
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia prime editing and CRISPR market, by service
7.5.5.2.2.Saudi Arabia prime editing and CRISPR market, by application
7.5.5.2.3.Saudi Arabia prime editing and CRISPR market, by end user
7.5.5.3.South Africa
7.5.5.3.1.South Africa prime editing and CRISPR market, by service
7.5.5.3.2.South Africa prime editing and CRISPR market, by application
7.5.5.3.3.South Africa prime editing and CRISPR market, by end user
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA prime editing and CRISPR market, by service
7.5.5.4.2.Rest of LAMEA prime editing and CRISPR market, by application
7.5.5.4.3.Rest of LAMEA prime editing and CRISPR market, by end user
CHAPTER 8:COMPANY PROFILES
8.1.Beam Therapeutics Inc
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments
8.2.CRISPR Therapeutics AG.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.Genscript Biotech Corporation.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Horizon Discovery, Ltd.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Integrated DNA Technologies (IDT).
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments
8.6.Intellia Therapeutics, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Key strategic moves and developments
8.7.Inscripta, Inc
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments
8.8.Precision Biosciences
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Sangamo Therapeutics.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Synthego Corporation.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Advancements in R&D in genetic engineering
3.5.1.2.Increase in demand for genetically modified crops
3.5.1.3.Surge in prevalence of chronic and genetic diseases
3.5.2.Restraints
3.5.2.1.Legal and ethical issues
3.5.2.2.Lack of safety toward gene editing
3.5.3.Opportunity
3.5.3.1.Increase in R&D by major key players and decrease in cost of genomic sequencing
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the prime editing and CRISPR market
CHAPTER 4:PRIME EDITING AND CRISPR MARKET, BY SERVICE
4.1.Overview
4.1.1.Market size and forecast
4.2.Cell line engineering
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Genome Regulation
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Gene editing
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Gene-modified cell therapy
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:PRIME EDITING AND CRISPR MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Biomedical research and therapy
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Agricultural Research
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Others
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
CHAPTER 6:PRIME EDITING AND CRISPR MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Academic institutions
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.2.4.Academic institutions, by application
6.3.Biotechnology & pharma companies
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.3.4.Biotechnology & pharma companies, by application
6.4.Contract Research Organizations
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
6.4.4.Contract research organizations, by application
CHAPTER 7:PRIME EDITING AND CRISPR MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America prime editing and CRISPR market, by service
7.2.3.North America prime editing and CRISPR market, by application
7.2.4.North America prime editing and CRISPR market, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. prime editing and CRISPR market, by service
7.2.5.1.2.U.S. prime editing and CRISPR market, by application
7.2.5.1.3.U.S. prime editing and CRISPR market, by end user
7.2.5.2.Canada
7.2.5.2.1.Canada prime editing and CRISPR market, by service
7.2.5.2.2.Canada prime editing and CRISPR market, by application
7.2.5.2.3.Canada prime editing and CRISPR market, by end user
7.2.5.3.Mexico
7.2.5.3.1.Mexico prime editing and CRISPR market, by service
7.2.5.3.2.Mexico prime editing and CRISPR market, by application
7.2.5.3.3.Mexico prime editing and CRISPR market, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe prime editing and CRISPR market, by service
7.3.3.Europe prime editing and CRISPR market, by application
7.3.4.Europe prime editing and CRISPR market, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany prime editing and CRISPR market, by service
7.3.5.1.2.Germany prime editing and CRISPR market, by application
7.3.5.1.3.Germany prime editing and CRISPR market, by end user
7.3.5.2.France
7.3.5.2.1.France prime editing and CRISPR market, by service
7.3.5.2.2.France prime editing and CRISPR market, by application
7.3.5.2.3.France prime editing and CRISPR market, by end user
7.3.5.3.UK
7.3.5.3.1.UK prime editing and CRISPR market, by service
7.3.5.3.2.UK prime editing and CRISPR market, by application
7.3.5.3.3.UK prime editing and CRISPR market, by end user
7.3.5.4.Italy
7.3.5.4.1.Italy prime editing and CRISPR market, by service
7.3.5.4.2.Italy prime editing and CRISPR market, by application
7.3.5.4.3.Italy prime editing and CRISPR market, by end user
7.3.5.5.Spain
7.3.5.5.1.Spain prime editing and CRISPR market, by service
7.3.5.5.2.Spain prime editing and CRISPR market, by application
7.3.5.5.3.Spain prime editing and CRISPR market, by end user
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe prime editing and CRISPR market, by service
7.3.5.6.2.Rest of Europe prime editing and CRISPR market, by application
7.3.5.6.3.Rest of Europe prime editing and CRISPR market, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific prime editing and CRISPR market, by service
7.4.3.Asia-Pacific prime editing and CRISPR market, by application
7.4.4.Asia-Pacific prime editing and CRISPR market, by end user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan prime editing and CRISPR market, by service
7.4.5.1.2.Japan prime editing and CRISPR market, by application
7.4.5.1.3.Japan prime editing and CRISPR market, by end user
7.4.5.2.China
7.4.5.2.1.China prime editing and CRISPR market, by service
7.4.5.2.2.China prime editing and CRISPR market, by application
7.4.5.2.3.China prime editing and CRISPR market, by end user
7.4.5.3.Australia
7.4.5.3.1.Australia prime editing and CRISPR market, by service
7.4.5.3.2.Australia prime editing and CRISPR market, by application
7.4.5.3.3.Australia prime editing and CRISPR market, by end user
7.4.5.4.India
7.4.5.4.1.India prime editing and CRISPR market, by service
7.4.5.4.2.India prime editing and CRISPR market, by application
7.4.5.4.3.India prime editing and CRISPR market, by end user
7.4.5.5.South Korea
7.4.5.5.1.South Korea prime editing and CRISPR market, by service
7.4.5.5.2.South Korea prime editing and CRISPR market, by application
7.4.5.5.3.South Korea prime editing and CRISPR market, by end user
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific prime editing and CRISPR market, by service
7.4.5.6.2.Rest of Asia-Pacific prime editing and CRISPR market, by application
7.4.5.6.3.Rest of Asia-Pacific prime editing and CRISPR market, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA prime editing and CRISPR market, by service
7.5.3.LAMEA prime editing and CRISPR market, by application
7.5.4.LAMEA prime editing and CRISPR market, by end user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil prime editing and CRISPR market, by service
7.5.5.1.2.Brazil prime editing and CRISPR market, by application
7.5.5.1.3.Brazil prime editing and CRISPR market, by end user
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia prime editing and CRISPR market, by service
7.5.5.2.2.Saudi Arabia prime editing and CRISPR market, by application
7.5.5.2.3.Saudi Arabia prime editing and CRISPR market, by end user
7.5.5.3.South Africa
7.5.5.3.1.South Africa prime editing and CRISPR market, by service
7.5.5.3.2.South Africa prime editing and CRISPR market, by application
7.5.5.3.3.South Africa prime editing and CRISPR market, by end user
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA prime editing and CRISPR market, by service
7.5.5.4.2.Rest of LAMEA prime editing and CRISPR market, by application
7.5.5.4.3.Rest of LAMEA prime editing and CRISPR market, by end user
CHAPTER 8:COMPANY PROFILES
8.1.Beam Therapeutics Inc
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments
8.2.CRISPR Therapeutics AG.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.Genscript Biotech Corporation.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Horizon Discovery, Ltd.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Integrated DNA Technologies (IDT).
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments
8.6.Intellia Therapeutics, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Key strategic moves and developments
8.7.Inscripta, Inc
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments
8.8.Precision Biosciences
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Sangamo Therapeutics.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Synthego Corporation.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 02.PRIME EDITING AND CRISPR MARKET FOR CELL LINE ENGINNERING, BY REGION, 2020–2030 ($MILLION)
TABLE 03.PRIME EDITING AND CRISPR MARKET FOR REGULATION OF GENE, BY REGION, 2020–2030 ($MILLION)
TABLE 04.PRIME EDITING AND CRISPR MARKET FOR GENE EDITING, BY REGION, 2020–2030 ($MILLION)
TABLE 05.PRIME EDITING AND CRISPR MARKET FOR GENE MODIFIED CELL THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 07.PRIME EDITING AND CRISPR MARKET FOR BIOMEDICAL RESEARCH AND THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 08.PRIME EDITING AND CRISPR MARKET FOR AGRICULTURAL RESEARCH, BY REGION, 2020–2030 ($MILLION)
TABLE 09.PRIME EDITING AND CRISPR MARKET FOR OTHER RESEARCH, BY REGION, 2020–2030 ($MILLION)
TABLE 10.GLOBAL PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 11.PRIME EDITING AND CRISPR MARKET FOR ACADEMIC INSTITUTIONS, BY REGION, 2020–2030 ($MILLION)
TABLE 12.ACADEMIC INSTITUTIONS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 13.PRIME EDITING AND CRISPR MARKET FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY REGION, 2020–2030 ($MILLION)
TABLE 14.BIOTECHNOLOGY & PHARMA COMPANIES, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 15.PRIME EDITING AND CRISPR MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY REGION, 2020–2030 ($MILLION)
TABLE 16.CONTRACT RESEARCH ORGANIZATIONS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 17.PRIME EDITING AND CRISPR MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 19.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 20.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 21.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 22.U.S. PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 23.U.S. PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.U.S. PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.CANADA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 26.CANADA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.CANADA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.MEXICO PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 29.MEXICO PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 30.MEXICO PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 31.EUROPE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 32.EUROPE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 33.EUROPE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 34.EUROPE PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 35.GERMANY PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 36.GERMANY PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.GERMANY PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.FRANCE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 39.FRANCE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 40.FRANCE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.UK PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 42.UK PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43.UK PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.ITALY PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 45.ITALY PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.ITALY PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.SPAIN PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 48.SPAIN PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 50.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 51.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 52.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 54.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 55.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 56.JAPAN PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 57.JAPAN PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 58.JAPAN PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 59.CHINA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 60.CHINA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 61.CHINA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 63.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 64.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 65.INDIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 66.INDIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 67.INDIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 69.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 70.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 74.LAMEA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 75.LAMEA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 76.LAMEA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 77.LAMEA PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 78.BRAZIL PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 79.BRAZIL PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 80.BRAZIL PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 82.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 83.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 85.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 86.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 88.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 89.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 90.BEAM: COMPANY SNAPSHOT
TABLE 91.BEAM: OPERATING SEGMENTS
TABLE 92.BEAM: PRODUCT PORTFOLIO
TABLE 93.CPISPR: COMPANY SNAPSHOT
TABLE 94.CRISPR: OPERATING SEGMENTS
TABLE 95.CRISPR: PRODUCT PORTFOLIO
TABLE 96.GENSCRIPT: COMPANY SNAPSHOT
TABLE 97.GENSCRIPT: OPERATING SEGMENTS
TABLE 98.GENSCRIPT: PRODUCT PORTFOLIO
TABLE 99.HORIZON: COMPANY SNAPSHOT
TABLE 100.HORIZON: OPERATING SEGMENTS
TABLE 101.HORIZON: PRODUCT PORTFOLIO
TABLE 102.IDT: COMPANY SNAPSHOT
TABLE 103.IDT: OPERATING SEGMENTS
TABLE 104.IDT: PRODUCT PORTFOLIO
TABLE 105.INTELLIA: COMPANY SNAPSHOT
TABLE 106.INTELLIA: OPERATING SEGMENTS
TABLE 107.INTELLIA: PRODUCT PORTFOLIO
TABLE 108.INSCRIPTA: COMPANY SNAPSHOT
TABLE 109.INSCRIPTA: OPERATING SEGMENTS
TABLE 110.INSCRIPTA: PRODUCT PORTFOLIO
TABLE 111.PRECISION COMPANY SNAPSHOT
TABLE 112.PRECISION: OPERATING SEGMENTS
TABLE 113.PRECISION: PRODUCT PORTFOLIO
TABLE 114.SANGAMO: COMPANY SNAPSHOT
TABLE 115.SANGAMO: OPERATING SEGMENTS
TABLE 116.SANGAMO: PRODUCT PORTFOLIO
TABLE 117.SYNTHEGO: COMPANY SNAPSHOT
TABLE 118.SYNTHEGO: OPERATING SEGMENTS
TABLE 119.SYNTHEGO: PRODUCT PORTFOLIO
TABLE 01.PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 02.PRIME EDITING AND CRISPR MARKET FOR CELL LINE ENGINNERING, BY REGION, 2020–2030 ($MILLION)
TABLE 03.PRIME EDITING AND CRISPR MARKET FOR REGULATION OF GENE, BY REGION, 2020–2030 ($MILLION)
TABLE 04.PRIME EDITING AND CRISPR MARKET FOR GENE EDITING, BY REGION, 2020–2030 ($MILLION)
TABLE 05.PRIME EDITING AND CRISPR MARKET FOR GENE MODIFIED CELL THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 07.PRIME EDITING AND CRISPR MARKET FOR BIOMEDICAL RESEARCH AND THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 08.PRIME EDITING AND CRISPR MARKET FOR AGRICULTURAL RESEARCH, BY REGION, 2020–2030 ($MILLION)
TABLE 09.PRIME EDITING AND CRISPR MARKET FOR OTHER RESEARCH, BY REGION, 2020–2030 ($MILLION)
TABLE 10.GLOBAL PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 11.PRIME EDITING AND CRISPR MARKET FOR ACADEMIC INSTITUTIONS, BY REGION, 2020–2030 ($MILLION)
TABLE 12.ACADEMIC INSTITUTIONS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 13.PRIME EDITING AND CRISPR MARKET FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY REGION, 2020–2030 ($MILLION)
TABLE 14.BIOTECHNOLOGY & PHARMA COMPANIES, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 15.PRIME EDITING AND CRISPR MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY REGION, 2020–2030 ($MILLION)
TABLE 16.CONTRACT RESEARCH ORGANIZATIONS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 17.PRIME EDITING AND CRISPR MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 19.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 20.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 21.NORTH AMERICA PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 22.U.S. PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 23.U.S. PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.U.S. PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.CANADA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 26.CANADA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.CANADA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.MEXICO PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 29.MEXICO PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 30.MEXICO PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 31.EUROPE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 32.EUROPE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 33.EUROPE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 34.EUROPE PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 35.GERMANY PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 36.GERMANY PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.GERMANY PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.FRANCE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 39.FRANCE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 40.FRANCE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.UK PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 42.UK PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43.UK PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.ITALY PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 45.ITALY PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.ITALY PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.SPAIN PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 48.SPAIN PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 50.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 51.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 52.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 54.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 55.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 56.JAPAN PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 57.JAPAN PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 58.JAPAN PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 59.CHINA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 60.CHINA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 61.CHINA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 63.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 64.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 65.INDIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 66.INDIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 67.INDIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 69.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 70.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 74.LAMEA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 75.LAMEA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 76.LAMEA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 77.LAMEA PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 78.BRAZIL PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 79.BRAZIL PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 80.BRAZIL PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 82.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 83.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 85.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 86.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 88.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 89.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 90.BEAM: COMPANY SNAPSHOT
TABLE 91.BEAM: OPERATING SEGMENTS
TABLE 92.BEAM: PRODUCT PORTFOLIO
TABLE 93.CPISPR: COMPANY SNAPSHOT
TABLE 94.CRISPR: OPERATING SEGMENTS
TABLE 95.CRISPR: PRODUCT PORTFOLIO
TABLE 96.GENSCRIPT: COMPANY SNAPSHOT
TABLE 97.GENSCRIPT: OPERATING SEGMENTS
TABLE 98.GENSCRIPT: PRODUCT PORTFOLIO
TABLE 99.HORIZON: COMPANY SNAPSHOT
TABLE 100.HORIZON: OPERATING SEGMENTS
TABLE 101.HORIZON: PRODUCT PORTFOLIO
TABLE 102.IDT: COMPANY SNAPSHOT
TABLE 103.IDT: OPERATING SEGMENTS
TABLE 104.IDT: PRODUCT PORTFOLIO
TABLE 105.INTELLIA: COMPANY SNAPSHOT
TABLE 106.INTELLIA: OPERATING SEGMENTS
TABLE 107.INTELLIA: PRODUCT PORTFOLIO
TABLE 108.INSCRIPTA: COMPANY SNAPSHOT
TABLE 109.INSCRIPTA: OPERATING SEGMENTS
TABLE 110.INSCRIPTA: PRODUCT PORTFOLIO
TABLE 111.PRECISION COMPANY SNAPSHOT
TABLE 112.PRECISION: OPERATING SEGMENTS
TABLE 113.PRECISION: PRODUCT PORTFOLIO
TABLE 114.SANGAMO: COMPANY SNAPSHOT
TABLE 115.SANGAMO: OPERATING SEGMENTS
TABLE 116.SANGAMO: PRODUCT PORTFOLIO
TABLE 117.SYNTHEGO: COMPANY SNAPSHOT
TABLE 118.SYNTHEGO: OPERATING SEGMENTS
TABLE 119.SYNTHEGO: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.PRIME EDITING AND CRISPR MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR REGULATION OF GENOME, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR GENE EDITING, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR GENE MODIFIED CELL THERAPY, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR BIOMEDICAL RESEARCH AND THERAPY, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR AGRICULTURAL RESEARCH, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR OTHER RESEARCH, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2020–2030 (%)
FIGURE 23.GENSCRIPT: NET SALES, 2018-2020 ($MILLION)
FIGURE 24.GENSCRIPT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 25.GENSCRIPT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26.HORIZON: NET SALES, 2017-2019 ($MILLION)
FIGURE 27.HORIZON: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.HORIZON: REVENUE SHARE BY REGION 2019 (%)
FIGURE 29.PRECISION: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.PRECISION: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.SANGAMO: NET SALES, 2018–2020 ($MILLION)
FIGURE 01.PRIME EDITING AND CRISPR MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR REGULATION OF GENOME, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR GENE EDITING, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR GENE MODIFIED CELL THERAPY, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR BIOMEDICAL RESEARCH AND THERAPY, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR AGRICULTURAL RESEARCH, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR OTHER RESEARCH, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2020–2030 (%)
FIGURE 23.GENSCRIPT: NET SALES, 2018-2020 ($MILLION)
FIGURE 24.GENSCRIPT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 25.GENSCRIPT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26.HORIZON: NET SALES, 2017-2019 ($MILLION)
FIGURE 27.HORIZON: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.HORIZON: REVENUE SHARE BY REGION 2019 (%)
FIGURE 29.PRECISION: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.PRECISION: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.SANGAMO: NET SALES, 2018–2020 ($MILLION)
